Successful Entrepreneur.  Healthcare Leader. Technology Executive. Published Researcher.

Proove Biosciences, Inc. , the Healthcare Decision Company™, today announced it ranked at number 69 on Deloitte's 2016 Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America from fiscal year 2012 to 2015. Proove Biosciences grew 1,386 percent during this period, further highlighting its already-renowned achievements in individualizing patient treatment through proprietary and patent-pending, comprehensive genetic testing methods.

"To be ranked 323 out of approximately 18,000,000 businesses in America is an incredible honor for the nearly 300 employees at Proove who are working tirelessly to make a difference in the world," says Proove founder and CEO, Brian Meshkin. "From Proove's inception, our mission has been focused on improving the quality of life of patients who are affected by our nation's largest and most expensive health condition -- pain. By delivering a portfolio of unique profiles that help physicians deliver patients with the finest health care experience, we are more than just a business -- we are doing our part to contribute to a healthier society." Proove's technologically-advanced suite of products addresses many common problems associated with pain, assesses serious issues surrounding dosing and addiction to opioid and prescription medication, and evaluates the effectiveness of treatment alternatives.
SmartCEO magazine has repeatedly awarded him as a top CEO and San Diego Magazine called him a Biotechnology “Power to Be” for his entrepreneurship.  But if you ask Brian, he considers himself a Social Entrepreneur.  Social entrepreneurs are individuals with innovative solutions to society's most pressing social problems. They are ambitious and persistent, tackling major social issues and offering new ideas for wide-scale change.
Brian is the founder and Chief Executive Officer of Proove Biosciences, the leader in personalized pain medicine.  Headquartered in Irvine, California, hundreds of physicians have ordered Proove’s proprietary genetic tests on over 75,000 patients to personalize their pain management.
Proove is an innovator tackling the major social problems of pain and opioid addiction.
“The reason why most people go to the doctor is because something hurts. It’s usually due to physical or emotional pain.  All doctors treat pain associated with ‘fill in the blank’. It’s the number reason why patients visit their primary care doctor. And now, pain is the most expensive condition in the U.S. healthcare system – more than cancer and heart disease combined.  So, Proove set out back in 2009 to tackle this issue.  We knew we could bring rational decision-making to these problems and help solve them.  But we also were committed to making a difference. You see when you help solve this problem, it’s more than just financial cost.  Three times as many people are addicted to and dying from legal narcotics than all of the illegal narcotics combined.  Can you believe it?  Even when you combine all of the heroin, cocaine, and other illegal narcotics, more people are being harmed by the ethical legal products prescribed by doctors, dispensed by pharmacies, and paid for by either employers or taxpayers than the illegal stuff. Now as this problem has become an epidemic, medicine abuse has become the leading cause of death among teenagers – outpacing automobile accidents.”
Proove is using social entrepreneurship and innovation to help solve these problems.  Proove offers patent-pending genetic testing and its proprietary bioinformatics platform to deliver treatment decision algorithms to improve healthcare decisions.  Simply put, Proove provides proof to improve healthcare decisions.  Just in 2014 alone, Proove testing saved the U.S. healthcare system over $200,000,000.

Not only is Proove’s testing unprecedented, but so is Proove’s rise to success.  Unlike many biotechnology companies who rely upon outside capital to start and grow, Brian and his wife, Catherine, started Proove as a “family business” investing their own capital and growing the business from its humble beginnings in the midst of the Great Recession in 2009. He explains,

“Winston Churchill said, ‘Success is never final. Failure is never fatal. It’s courage that counts.’  Well back then, it was courage and faith that kept me going.  The worldwide stock market crash all but killed a little company that my friend Ralph and I had started together.  And then the real estate meltdown all but destroyed our family financially. It was like a one-two punch.  We had moved to Maryland as my wife was in law school and now everything was melting around us. It was at this lowest low that I started Proove. It was a concept and a company that I had talked about since 2004 and I felt I could do it.  After 18 months of pilot studies, I had even more doubts as I had exhausted every ounce of resources.  But it was then, that I relied upon on my wife’s faith and encouragement, and the support of my kids, to give the business the lift it needed.  In the summer of 2011, our family drove from Maryland to Southern California so I could do everything to grow Proove – collecting specimens, selling more doctors, billing insurers, and more.   That summer, our family lived with extended family and friends for two months while I did everything I could to commercially launch the business.”
In the summer of 2011, Brian hired his first employee in California. Returning in August, Brian hired his second employee – the first in Maryland.  In 2012, Proove hired 20 more. In 2013, Proove hired 40 more.  In 2014, Proove hired 120 more. And the Company is still growing.  Today, Proove is a thriving and profitable personalized medicine company with about 200 employees across the nation.  Unlike many other molecular diagnostic companies, Proove has more than one product, is profitable, has no shareholder deficit, and is growing.

From 2012 through 2014, Proove has grown from physicians ordering 30,000 tests on 2,500 panels in 2012 to over 1,300,000 tests on over 50,000 gene panels in 2014 – a staggering growth rate of over 4,200%.

From 2012 through 2014, Proove has grown from 6 employees to over 180 employees – an extremely fast growth rate of 2,900%. In 2013, the Greater Baltimore Committee awarded Brian and his wife a 2013 Bridging the Gap Award as a successful, thriving minority-owned business.  

In addition to Proove, Brian has been involved in other entrepreneurial endeavors.  Having served as a Professor of Entrepreneurship at Howard Community College and on the Advisory Board of its Center for Business Excellence and Entrepreneurship, Brian introduced social entrepreneurship into the curriculum and program.  He was proud to help his students plan and launch their business ideas, including a student he worked with as a business coach, Joaness Christie, who is now the proud owner of La Pearl Waffles in Howard County, Maryland. 

Brian has always had a passion for new technologies as he is a published scientific author. (hyperlink to bibliography of publications) Prior to Proove, Brian was the co-founder and CEO of Salugen, a nutritional genetics company that offered direct-to-consumer genetic testing and customized nutritional products.  Previously, Brian was with Prometheus Laboratories, Johnson & Johnson, and Eli Lilly & Company.

Pubilications

Meshkin, B., Lewis, K., Kantorovich, S., Anand, N., & Davila, L. (2015, December). Adding Genetic Testing to Evidence-Based Guidelines to Determine the Safest and Most Effective Chronic Pain Treatment for Injured Workers. International Journal of Biomedical Science, 11(4), 157-165.    

Dervieux T, Meshkin B, Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res. 2005 Jun 3;573(1-2):180-94. 

Blum K, Meshkin B, Downs BW. DNA based customized nutraceutical “gene therapy” utilizing a genoscore: A hypothesized paradigm shift of a novel approach to the diagnosis, stratification, prognosis and treatment of inflammatory processes in the human. Medical Hypothesis. 66:5, 1008-1018, 2006.

Comings DE, Chen TJH, Blum K, Mengucci J, Blum SH and Meshkin B. Neurogenetic interactions and aberrant behavioral comorbidity of attention deficit hyperactivity disorder (ADHD): dispelling myths. Theoretical Biology and Medical Modeling 2:50, 2005.

Blum K, Chen TJH, Blum S, Downs WB, Braverman E, Mengucci J, Meshkin B. Nutrigenomics & pharmacogenomics: A scientific wonderland. Biology Of Social Life. Vol 45 (1), pp. 35-52: 061102. 

Blum K, Nicholas A, DiNubile N, Chen TJH, Waite RL, Schoolfield J, Blum SH, Mengucci J, and Meshkin B. H-Wave: an Alternative Non-Pharmacological Approach to Lower Extremity Pain: A Preliminary Evaluation. Adv Ther. 2006 Sep-Oct;23(5):739-49.

Blum K, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mangucci JF, Braverman ER, Arcuri V, Deutsch R, Pons MM. Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: Hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). Med Hypotheses. 2006 Oct 27; [Epub ahead of print]. 

Meshkin B, Blum K. Folate Nutrigenetics: A Convergence of Dietary Folate Metabolism, Folic Acid Supplementation, and Folate Antagonist Pharmacogenetics. Drug Metabolism Letters, 2007, 1, 55-60.

Blum K, Chen TJK, Blum SH, Comings DE, Mengucci JF, Meshkin B, Downs BW, Martinez-Pons M, Braverman ER. Reward Deficiency Syndrome (RDS): Neurogenetic aspects of aging and related behavioral disorders specific to dopaminergic pathways. Anti-Aging Therapeutics, 8: 9-26 2006.

Blum K, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mengucci JF, Braverman ER, Arcuri V, Varshavskiy M, Deutsch R, Martinez-Pons M. Reward deficiency syndrome in obesity: a preliminary cross-sectional trial with a Genotrim variant. Adv Ther. 2006 Nov-Dec;23(6):1040-51. rian Meshkin CV Page 4.

Chen TJ, Blum K, Waite RL, Meshkin B, Schoolfield J, Downs BW, Braverman EE, Arcuri V, Varshavskiy M, Blum SH, Mengucci J, Reuben C, Palomo T. Gene narcotic attenuation program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome. Adv Ther. 2007 Mar-Apr;24(2):402-14.

Blum K, Chen TJ, Meshkin B, Waite RL, William Downs B, Blum SH, Mengucci JF, Arcuri V, Braverman ER, Palomo T. Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: A hypothesis. Med Hypotheses. 2007 Apr 27; [Epub ahead of print]

Blum K, Chen TJH, Downs BW, Meshkin B, Blum SH, Martinez Pons M, Mengucci JF, Waite RL, Arcuri V, Varshofsiky M, Braverman ER. Synaptamine (SG8839)™ An Amino-Acid Enkephalinase Inhibition Nutraceutical Improves Recovery Of Alcoholics, A Subtype Of Reward Deficiency Syndrome (RDS). Trends in Applied Sciences Research. 2(2): 132-138, 2007. 

Blum K, Chen TJH, Meshkin B, Blum SH, Mengucci JF, Arcuri V, Waite RL, Braverman ER. The PPAR-gamma Pro12Ala allele polymorphism of the Peroxisome Proliferator-Activated Receptor (gamma) Gene (PPARG2) Is a Risk Factor With a Self-Identified Obese Dutch Population. Gene Ther Mol Biol Vol 11, 37-42, 2007.

Chen TJH, Blum K, Mathews D, Fisher L, Schnautz N, Braverman E, Schoolfield J, Downs BW, Blum SH, Mengucci J, Meshkin B, Acuri V, Bajaj A, Comings DE. Preliminary Association of Both The Dopamine D2 Receptor (DRD2) [Taq1 A1 Allele] And The Dopamine Transporter (DAT1) [480 bp Allele] Genes With Pathological Aggressive Behavior, A Clinical Subtype Of Reward Deficiency Syndrome (RDS) in Adolescents. Gene Therapy and Mol Biol.Volume 11, 93-112,2007

Chen TJH, Blum K, Kaats G, Braverman E, Pullin D, Downs BW, Martinez-Pons M, Blum SH, Mengucci J, Bagchi D, Bagchi M, Robarge A, Meshkin B, Acuri V, Varshavskiy, Notaro A, Comings DE, White L.. Reviewing the role of putative candidate genes in “Neurobesigenics,” a clinical subtype of Reward Deficiency Syndrome (RDS). Gene Ther Mol Biol. Vol 11, 61-74, 2007.

Chen TJH, Blum K, Kaats G, Braverman ER, Eisenberg A, Sherman M, Davis K, Comings DE, Wood R, Pullin D, Arcuri V, Varshavski M, Mengucci JF, Blum SH, Downs BW, Meshkin B, Waite RL, Williams L, Schoolfield J, Prihoda TJ, White L. Chromium Picolinate (CrP) a putative anti-obesity nutrient induces changes in body composition as a function of the Taq1 dopamine D2 receptor polymorphisms in a randomized double-blind placebo controlled study. Gene Ther Mol Biol Vol 11, 161-170, 2007.

Braverman ER, Chen TJH, Prihoda TJ, Sonntag W, Meshkin B, Downs BW, Mengucci JF, Blum SH, Notaro A, Arcuri V, Varshavskiy M, Blum K. Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: Evidence supported by structural equation modeling (SEM) parameter estimates. Age (Dordr). 2007 September; 29(2-3): 55–67.

Deer T, Smith GA, Meshkin B, Hubbard J, Sinel M, Arthur B. Pilot Investigate Of The Likely Linkage (P.I.L.L.) Between Genetic Variations In The Mesolimbic Dopamine System And Elevated Risk Of Opioid Abuse In Choice Pain Patients. J Addict Med. Volume 7, Number 4, July/August 2013.

Meshkin B, Arthur B. Likely linkage: genetic variations in the mesolimbic dopamine system and elevated risk of opioid abuse in chronic pain patients. J Pain, Vol. 14, Issue 4, Supplement S8.

Chang S, Onojighofia T, Smith G, Deer T, Webster L, Trescott A, Sinel M, Zoleikhaeian M, Hua M, Hubbard J, Meshkin B. Retrospective Analysis of the Clinical and Economic Results (R.A.C.E.R.) of Genotyping Chronic Pain Patients to Guide Medical Detoxification of Prescription Opioid Analgesic Abuse (RxO): Two-Year Study. J Pain, Vol. 14, Issue 4, Supplement, Page S38.

Chang S. Onojighofia, T. Deer T, Webster L, Trescott A, Smith G, Sinel M, Zoleikhaeian M, Hubbard J, Meshkin B. Investigation Of Genetic Variations In The Mesolimbic Dopamine System And Elevated Risk Of Opioid Abuse In Chronic Pain Patients. ASRA-0197, Reg Anesth Pain Med, Fall 2013. 

Akindele B., Meshkin B., Schwarz D., Hubbard J., Holman D., Knauer M., Onojighofia T. “5HT2a Meshkin B., Schwarz D., Akindele B., Hubbard J., Holman D., Anand N., Onojighofia T. “Role of Meshkin B., Schwarz D., Akindele B., Hubbard J., Holman D., Anand N., Onojighofia T. “Genetics Meshkin B., Schwarz D., Akindele B., Hubbard J., Holman D., Anand N., Onojighofia T. “Gender B. Akindele, MD; R. Alexander, PhD; M. Knauer, PhD; D. Schwarz, MD; T. Onojighofia, MD; B. B. Akindele, MD; R. Alexander, PhD; M. Knauer, PhD; D. Schwarz, MD; T. Onojighofia, MD; Understanding the Problem of Prescription Drug Abuse using Genetic Testing in Chronic Pain Patients.

B. Meshkin, B. Akindele, D. Schwarz, J. Hubbard, D. Holman, S.V. Nguyen, T. Onojighofia. “GENETICS B. Meshkin, B. Akindele, D. Schwarz, J. Hubbard, D. Holman, S.V. Nguyen, T. Onojighofia. “OBSERVATIONAL B. Meshkin, B. Akindele, D. Schwarz, J. Hubbard, D. Holman, S.V. Nguyen, T. Onojighofia. "GENETICS B. Meshkin, B. Akindele, D. Schwarz, J. Hubbard, D. Holman, S.V. Nguyen, T. Onojighofia. "Gender Onojighofia T., Meshkin B., Schwarz D., Akindele B., Hubbard J., Nguyen S.V. " Presented by Mary B. Akindele, MD; R. Alexander, PhD; M. Knauer, PhD; D. Schwarz, MD; T. Onojighofia, MD; B. Meshkin B., Schwarz D., Akindele B., Hubbard J., Holman D., Nguyen S.V., Alexander R., Knauer Onojighofia T., Meshkin B., Schwarz D., Akindele B., Hubbard J., Holman D., Nguyen S.V." Methylenetetrahydrofolate B. Akindele, B. Meshkin, D. Schwarz, J. Hubbard, D. Holman, S.V. Nguyen, T. Onojighofia.

Alderson N., Doust M., Meshkin B., Schwarz D., Akindele B., Hubbard J., Holman D., Nguyen S.Alderson N., Doust M., Meshkin B., Schwarz D., Akindele B., Hubbard J., Holman D., Nguyen S.Schwarz D., Akindele B., Onojighofia T., Hubbard J., Meshkin B., Chen D. "Investigation of Genetic Schwarz D., Akindele B., Onojighofia T., Hubbard J., Meshkin B., Chen D. "Investigation of Genetic Schwarz D., Akindele B., Onojighofia T., Hubbard J., Meshkin B., Chen D., Holman D.. "Perception Schwarz D., Akindele B., Onojighofia T., Hubbard J., Meshkin B., Chen D. "Investigation of Genetic Schwarz D., Meshkin B., Trescot A., Silverman S., Akindele B., Hubbard J., Holman D., Nguyen Akindele B., Meshkin B., Schwarz D., Deer T., Webster L., Trescott A., Smith G., Sinel M., Zoleikhaeian Schwarz D., Akindele B., Onojighofia T., Hubbard J., Meshkin B., Chen D., Holman D.. "Perception Schwarz D., Meshkin B., Trescot A., Silverman S., Akindele B., Hubbard J., Holman D., Nguyen Schwarz D., Meshkin B., Trescot A., Silverman S., Akindele B., Hubbard J., Holman D., Nguyen Schwarz D., Meshkin B., Trescot A., Silverman S., Akindele B., Hubbard J., Holman D., Nguyen Onojighofia T., Meshkin B., Schwarz D.,Akindele B.,Smith D., Deer T., Webster L., Zoleikhaeian Onojighofia T., Meshkin B., Schwarz D.,Akindele B.,Smith D., Deer T., Webster L., Zoleikhaeian Onojighofia T., Akindele B., Deer T., Webster L., Trescott A., Smith G., Sinel M., Zoleikhaeian M., Chang S., Onojighofia T., Deer T., Webster L., Trescott A., Smith G., Sinel M., Zoleikhaeian M., Trescott A. "Pharmacogenetics of pain management." Presented at California Society of Interventional Chang S., Onojighofia T., Smith G., Deer T., Webster L., Trescott A., Sinel M., Zoleikhaeian M., Chang S., Onojighofia T., Smith G., Deer T., Webster L., Trescott A., Sinel M., Zoleikhaeian M.

Chang S., Onojighofia T., Smith G., Deer T., Webster L., Trescott A., Sinel M., Zoleikhaeian M., Chang S., Onojighofia T., Smith G., Deer T., Webster L., Trescott A., Sinel M., Zoleikhaeian M., B.Meshkin. "Personalized Pain Medicine: The Importance of Pharmacogenetic Testing in Pain Management." Chang S., Onojighofia T., Smith G., Deer T., Webster L., Trescott A., Sinel M., Zoleikhaeian M., Deer T., Smith G., Meshkin B., Hubbard J., Sinel M., Arthur B. “Investigation of Genetic Variations Deer T., Smith G., Meshkin B., Hubbard J., Sinel M., Arthur B. “Investigation of Genetic Variations Chang S., Onojighofia T., Smith G., Deer T., Webster L., Trescott A., Sinel M., Zoleikhaeian M., B.Arthur. “Investigation of Genetic Variations in the Mesolimbic Dopamine System and Elevated B. Arthur. "Retrospective Analysis of the Clinical and Economic Results (R.A.C.E.R.) of Genotyping Deer T., Smith G., Meshkin B., Hubbard J., Sinel M., Arthur B. “Investigation of Genetic Variations

Knauer M., Onojighofia T. “5HT2a and Mental Disorders: Multi-Center Study to Determine Association of Genetic Anand N., Onojighofia T. “Role of OPRM1 in Risk of Opioid Abuse; Relationship between OPRM1 and SOAPPAnand N., Onojighofia T. “Genetics And Drug Response: Study on the Influence of Genetic Variation on Morphine Anand N., Onojighofia T. “Gender Difference In The Response to Tramadol In Pain Patients”. Presented by Bilikis Schwarz, MD; T. Onojighofia, MD; B. Meshkin; D. Holman, MD; J. Hubbard, RPT; S.V. Nguyen, MD. "Observational Schwarz, MD; T. Onojighofia, MD; B. Meshkin; D. Holman, MD; J. Hubbard, RPT; S.V. Nguyen, MD."Genetics Genetic Testing in Chronic Pain Patients.

V. Nguyen, T. Onojighofia. “GENETICS AND DRUG RESPONSE: ROLE OF GENETICS IN ANALGESIC V. Nguyen, T. Onojighofia. “OBSERVATIONAL STUDY TO CALCULATE ADDICTIVE RISK TO NARCOTICS V. Nguyen, T. Onojighofia. "GENETICS AND DRUG RESPONSE: STUDY ON THE ROLE OF GENETICS V. Nguyen, T. Onojighofia. "Gender Differences versus Genotype Risk of CoMorbidities in Chronic Pain Patients". Nguyen S.V. " Presented by Mary Knauer, PhD, at (American Psychiatric Association) Institute on Psychiatric Schwarz, MD; T. Onojighofia, MD; B. Meshkin; D. Holman, MD; J. Hubbard, RPT; S.V. Nguyen, MD. Presented Nguyen S.V., Alexander R., Knauer M., Onojighofia T. "Multi-Center Study to Evaluate Accuracy of the Medication Holman D., Nguyen S.V." Methylenetetrahydrofolate Reductase (MTHFR) and Risk of Opioid abuse. Study V. Nguyen, T. Onojighofia.

Hubbard J., Holman D., Nguyen S.V., Chen J., Onojighofia T. "Gender Differences versus Genotype Risk of Co-Hubbard J., Holman D., Nguyen S.V., Chen J., Onojighofia T. "Racial Differences versus Genotype Risk of Co-Chen D. "Investigation of Genetic Variations in the Mesolimbic Dopamine System and Elevated Risk of Opioid Chen D. "Investigation of Genetic Variations in the Mesolimbic Dopamine System and Elevated Risk of Opioid Chen D., Holman D.. "Perception of Analgesia in Narcotic Users with Chronic Pain: A Multi-Center Cross-Chen D. "Investigation of Genetic Variations in the Mesolimbic Dopamine System and Elevated Risk of Opioid Hubbard J., Holman D., Nguyen S., Onojighofia T. "Analgesia Perception of Prescription Opioids with Chronic Trescott A., Smith G., Sinel M., Zoleikhaeian M., Hubbard J., Nguyen S.V., Onojighofia T.."Co-occuring Psychiatric Chen D., Holman D.. "Perception of Analgesia in Narcotic Users with Chronic Pain: A Multi-Center Cross-Hubbard J., Holman D., Nguyen S., Onojighofia T. "Predisposing Risk in Injury Claims Exceeding 1yr: Predictive Hubbard J., Holman D., Nguyen S., Onojighofia T. "Multi-Center Study to Evaluate Accuracy of the Medication Hubbard J., Holman D., Nguyen S., Onojighofia T. "Perception of Analgesia in Narcotic Users with Chronic Deer T., Webster L., Zoleikhaeian A., Hua M., Hubbard J., Chang S. "Stratifying Patient Opioid Risk Tool (ORT) Deer T., Webster L., Zoleikhaeian A., Hua M., Hubbard J., Chang S. "Study Investigating a Genetic Dependence Smith G., Sinel M., Zoleikhaeian M., Hua M., Hubbard J., Meshkin B., Chang S. "Observational Study to Calculate G., Sinel M., Zoleikhaeian M., Hubbard J., Meshkin B. "Investigation of Genetic Variations in the Mesolimbic California Society of Interventional Pain Physician CASIPP (CME), New Port Beach, CA by Andrea Trescott. A., Sinel M., Zoleikhaeian M., Hua M., Hubbard J., Meshkin B. "Retrospective Analysis of the Clinical and A., Sinel M., Zoleikhaeian M., Hua M., Hubbard J., Meshkin B. "Observational Study to Calculate Addictive

A., Sinel M., Zoleikhaeian M., Hua M., Hubbard J., Meshkin B. "Observational Study to Calculate Addictive A., Sinel M., Zoleikhaeian M., Hua M., Hubbard J., Meshkin B."Retrospective Analysis of the Clinical and Pharmacogenetic Testing in Pain Management." Presented at the Meeting of the West Virginia Society of Interventional A., Sinel M., Zoleikhaeian M., Hua M., Hubbard J., Meshkin B. "Observational Study to Calculate Addictive Investigation of Genetic Variations in the Mesolimbic Dopamine System and Elevated Risk of Opioid Abuse Investigation of Genetic Variations in the Mesolimbic Dopamine System and Elevated Risk of Opioid Abuse A., Sinel M., Zoleikhaeian M., Hua M., Hubbard J., Meshkin B. "Retrospective Analysis of the Clinical and Dopamine System and Elevated Risk of Opioid Abuse in Chronic Pain Patients.” Journal of Pain Vol. 14, Issue Results (R.A.C.E.R.) of Genotyping Chronic Pain Patients to Guide Medical Detoxification of Prescription Investigation of Genetic Variations in the Mesolimbic Dopamine System and Elevated Risk of Opioid Abuse.

Determine Association of Genetic Polymorphisms and Mental Disorders”. Presented by Bilikis Akindele, MD, Relationship between OPRM1 and SOAPP®-R Test”. Presented by Bilikis Akindele, MD, MMCi. at American Academy of Genetic Variation on Morphine Response”. Presented by Bilikis Akindele, MD, MMCi. at American Academy Pain Patients”. Presented by Bilikis Akindele, MD, MMCi. at American Academy of Pain Medicine Annual Meeting. S.V. Nguyen, MD. "Observational Study to Calculate Addictive Risk to Narcotics Due to Genetic Predisposition". S.V. Nguyen, MD."Genetics and Drug Response: Influence of variations in ANKK1 and DBH in Individual GENETICS IN ANALGESIC RESPONSE VARIATIONS IN CHRONIC PAIN PATIENTS TAKING OXYCODONE.” ADDICTIVE RISK TO NARCOTICS DUE TO GENETIC PREDISPOSITION IN CHRONIC PAIN PATIENTS.” ON THE ROLE OF GENETICS IN ANALGESIC RESPONSE VARIATIONS IN CHRONIC PAIN PATIENTS CoMorbidities in Chronic Pain Patients". Presented by Derrick Holman MD, at the American Academy of Physical Association) Institute on Psychiatric Services Meeting, November 2014.

S.V. Nguyen, MD. Presented by Mary Knauer, PhD, at American Academy of Addiction Psychiatry 25th Annual Evaluate Accuracy of the Medication Efficacy Differentiation (MED) Scale to Predict Hydrocodone Efficacy and Risk of Opioid abuse. Study on the association of MTHFR and SOAPP-R & ORT test." Presented by Roberta Differences versus Genotype Risk of Co-Morbidities in Chronic Pain Patients." Presented by Derrick Holman, MD., at versus Genotype Risk of Co-Morbidities in Chronic Pain Patients." Presented by Derrick Holman, MD., at System and Elevated Risk of Opioid Abuse in Chronic Pain Patients.” Presented at the, Presented at the 21st Annual System and Elevated Risk of Opioid Abuse in Chronic Pain Patients.” Presented at the, Presented at Pain Week Chronic Pain: A Multi-Center Cross-Sectional Study Comparing Genotype to Pain VAS." Presented at Pain Week System and Elevated Risk of Opioid Abuse in Chronic Pain Patients.” Presented at the, International Conference Prescription Opioids with Chronic Pain: Comparing Genotype to Pain VAS."

Onojighofia T.."Co-occuring Psychiatric Predisposition May Affect Response to the Treatment of Chronic Pain: A Prevalence Chronic Pain: A Multi-Center Cross-Sectional Study Comparing Genotype to Pain VAS." Presented at American Society Claims Exceeding 1yr: Predictive Assessment using Pharmacogenetics." Presented at American Society of Evaluate Accuracy of the Medication Efficacy Differentiation (MED) Scale to Predict Hydrocodone Efficacy versus Narcotic Users with Chronic Pain: A Multi-Center Cross-Sectional Study Comparing Genotype to Pain VAS Patient Opioid Risk Tool (ORT) Scores Using Genetic Predisposition of Dopaminergic Imbalances." Presented Investigating a Genetic Dependence Risk Index of Variants Effect on Risk for Co-morbid Psychiatric Disorders Observational Study to Calculate Addictive Risk to Narcotics Due to Genetic Predisposition in Chronic Pain Genetic Variations in the Mesolimbic Dopamine System and Elevated Risk of Opioid Abuse in Chronic Pain Patients.” Beach, CA by Andrea Trescott. 2013.

Analysis of the Clinical and Economic Results (R.A.C.E.R.) of Genotyping Chronic Pain Patients to Guide Observational Study to Calculate Addictive Risk to Narcotics Due to Genetic Predisposition in chronic pain patients." 

Presented Observational Study to Calculate Addictive Risk to Narcotics Due to Genetic Predisposition in chronic pain patients." Presented Analysis of the Clinical and Economic Results (R.A.C.E.R.) of Genotyping Chronic Pain Patients to Guide West Virginia Society of Interventional Pain Physicians (WVSIPP) and American Academy of Pain Medicine Observational Study to Calculate Addictive Risk to Narcotics Due to Genetic Predisposition in chronic pain patients." Presented Elevated Risk of Opioid Abuse in Chronic Pain Patients.” Presented at American Pain Society Annual Scientific Elevated Risk of Opioid Abuse in Chronic Pain Patients.” American Society of Addiction Medicine Annual Medical Analysis of the Clinical and Economic Results (R.A.C.E.R.) of Genotyping Chronic Pain Patients to Guide Patients.” Journal of Pain Vol. 14, Issue 4, Supplement, Page S8, 2013.

Detoxification of Prescription Opioid Analgesic Abuse (RxO): Two-Year Study." Journal of Pain, The Vol. 14, Elevated Risk of Opioid Abuse in Chronic Pain Patients.” Journal of Addiction Medicine Volume 7 - Issue 4 Med.